RARE DISEASE
Pantothenate kinase-associated neurodegeneration
Pantothenate kinase-associated neurodegeneration
Pantothenate kinase-associated neurodegeneration
Synonyms: Hallervorden-Spatz syndrome, NBIA1, Neurodegeneration with brain iron accumulation type 1, PKAN
Synonyms: Hallervorden-Spatz syndrome, NBIA1, Neurodegeneration with brain iron accumulation type 1, PKAN
Synonyms: Hallervorden-Spatz syndrome, NBIA1, Neurodegeneration with brain iron accumulation type 1, PKAN
Drug discovery
6
drugs
With orphan designations
Overview
Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive disorder caused by PANK2 mutations, leading to impaired coenzyme A metabolism and iron accumulation in the basal ganglia. It manifests with dystonia, rigidity, dysarthria, and progressive neurodegeneration. Classic PKAN (75% of cases) presents before age 6 with rapid progression, while atypical PKAN (25%) has later onset and slower decline [1][2][6]. Diagnosis relies on MRI showing the "eye-of-the-tiger" sign and genetic confirmation [2][12]. Symptomatic care remains the mainstay, as no disease-modifying therapies exist [3][8].
Burden
High morbidity: 55% require gastrostomy; 100% need full-time care in advanced stages [5][12]
Frequent hospitalizations: ~13 medical visits/year, often for pneumonia or nutritional crises [5]
Mortality: Median survival 11 years post-diagnosis; death typically from aspiration or status dystonicus [1][2]
Therapies
Symptomatic management: Baclofen, anticholinergics, botulinum toxin, and deep brain stimulation for dystonia [2][8]
Iron chelation: Deferiprone reduces cerebral iron but limited clinical impact [8][12]
Investigational approaches: PANK activators, CoA prodrugs (e.g., fosmetpantotenate), and gene therapy [3][11]
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders
Research Papers
200 drug discovery papers about Pantothenate kinase-associated neurodegeneration, with 1 first-in-class and 12 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
200 drug discovery papers about Pantothenate kinase-associated neurodegeneration, with 1 first-in-class and 12 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-15 | From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis.
Coenzyme A (CoA) biosynthesis is a conserved, dynamically regulated pathway essential for mitochondrial energy production, fatty acid oxidation, lipid biosynthesis and protein acylation. Biallelic variants in PANK2, PPCS, PPCDC, and COASY cause rare inborn errors of CoA biosynthesis, associated with markedly different clinical phenotypes: PANK2 and COASY defects predominantly cause neurological disorders within or adjacent to the neurodegeneration with brain iron accumulation (NBIA) spectrum, whereas PPCS and PPCDC deficiencies present mainly as severe early-onset dilated cardiomyopathy. However, COASY variants can also cause pontocerebellar hypoplasia and riboflavin-responsive lipid storage myopathy. This review examines these four disorders from a metabolic perspective, integrating clinical features, experimental models, biochemical data and emerging therapeutic approaches. Current evidence indicates that disease pathogenesis cannot be explained only by global CoA depletion. Total CoA levels may be reduced in PPCS and PPCDC deficiency, but are often preserved under basal conditions in PKAN and COASY-related models. Instead, impaired compartment-specific CoA handling and failure to sustain CoA-dependent flux under increased metabolic demand are emerging as central pathogenic concepts. Perturbation of fatty acid handling, acyl-CoA/acylcarnitine balance, mitochondrial function, iron homeostasis, protein acylation and 4'-phosphopantetheinylation may contribute to tissue-selective vulnerability. Therapeutic strategies are therefore likely to require disease-specific approaches, including precursor bypass or PANK activation where pathway flux can be restored, early pantethine supplementation in cardiomyopathic forms, and downstream or gene-directed strategies for COASY-related disorders. Understanding CoA as a regulator of metabolic adaptability provides a unifying framework for interpreting both shared mechanisms and disease divergence.
2026-07-28 | Pantethine and Neurodegeneration: A Coenzyme ACentered Framework Linking Metabolism, Neuroinflammation, and Mitochondrial Dysfunction
Neurodegenerative diseases are a growing global health burden associated with aging and characterized by progressive neuronal dysfunction, metabolic failure, mitochondrial impairment, oxidative stress, and chronic neuroinflammation. Among the metabolic pathways implicated in these disorders, coenzyme A (CoA)-linked biology has emerged as a potentially important but still underexplored contributor to neuronal resilience and vulnerability. Pantethine, a disulfide derivative of pantetheine and a CoA-related metabolic precursor, has attracted attention because of its reported effects on cellular metabolism, redox balance, and inflammatory signaling. However, its relevance across neurodegenerative diseases remains unevenly defined, with direct support strongest in pantothenate kinase-associated neurodegeneration (PKAN) and more limited evidence in common disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). This narrative review critically examines the mechanistic and translational evidence linking pantethine to neurodegeneration. PKAN represents the most logical disease context for pantethine investigation because impaired CoA biosynthesis is proximal to disease pathogenesis, although pantethine remains investigational and its clinical efficacy has not been established. By contrast, proposed applications in AD and PD remain highly theoretical and hypothesis-generating. Nevertheless, research on pantethine and related CoA-restoring strategies may identify new intervention targets across neurodegenerative diseases and other disorders characterized by impaired cellular bioenergetics, including selected neuropsychiatric disorders. These possibilities require biomarker-informed, disease-specific studies that establish active-species exposure, target engagement, and clinically meaningful effects.
2026-07-10 | Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges
Neurodegeneration with brain iron accumulation (NBIA) comprises a group of rare genetic movement disorders characterized by progressive neurological deterioration, dystonia, parkinsonism, spasticity, and abnormal iron deposition in the basal ganglia. Although iron accumulation is the shared neuroradiological hallmark, most NBIA genes do not directly regulate iron metabolism. Instead, major NBIA forms arise from disruption of distinct but converging cellular pathways, including coenzyme A (CoA) biosynthesis, lipid metabolism, mitochondrial function, and autophagy. This narrative review aims to examine the pathogenic mechanisms of major NBIA disorders, namely pantothenate kinase-associated neurodegeneration (PKAN), COASY protein-associated neurodegeneration (CoPAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and beta-propeller protein-associated neurodegeneration (BPAN), and how these insights are guiding therapeutic development. Preclinical strategies aimed at restoring CoA metabolism, improving mitochondrial function, limiting lipid peroxidation, modulating autophagy, or correcting the underlying genetic defect have shown encouraging results, although none have yet reached robust clinical validation. Clinical translation remains limited by disease rarity, clinical heterogeneity, absence of validated biomarkers, and preclinical models that only partially recapitulate human pathology. Advancing the field will depend on earlier molecular diagnosis, biomarkers capable of tracking disease stage, and trial designs suited to ultra-rare populations. NBIA thus offers a paradigm for how mechanistic classification of a genetically defined disease group can redirect therapeutic strategy away from a shared radiological feature and toward pathway-specific intervention.
2026-04-30 | Neurodegeneration with Brain Iron Accumulation PANK2 and PLA2G6 Related Disorders
Abstract: Background Neurodegeneration with Brain Iron Accumulation (NBIA) disorders are rare inherited conditions characterized by progressive motor and cognitive decline due to iron deposition in the basal ganglia and cerebellum. Among the eleven genetic subtypes, Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Phospholipase A₂-Associated Neurodegeneration (PLAN) are the best-characterized models linking disrupted iron metabolism to neurodegeneration. This review synthesizes current knowledge on the molecular basis, clinical features, diagnostic challenges, and emerging therapies for PKAN and PLAN. Conclusion PKAN and PLAN result from mutations in PANK2 and PLA2G6, respectively, disrupting coenzyme A synthesis and membrane lipid remodeling. These defects lead to mitochondrial dysfunction, oxidative stress, lipid peroxidation, and ultimately ferroptosis (an iron-dependent cell death pathway). Neuroimaging, particularly the “eye-of-the-tiger” sign in PKAN and cerebellar atrophy with optic atrophy in PLAN, aids diagnosis, though genetic testing remains definitive. Current management is symptomatic, but emerging therapies, including gene therapy, iron chelation, deuterated lipids (RT001), and enzyme activators hold promise for disease modification. A practical diagnostic algorithm is proposed to facilitate early recognition. Integrative longitudinal research is essential to clarify disease progression and optimize treatment timing.
2026-04-16 | PPARγ activation by leriglitazone counteracts neurodegeneration and neuroinflammation in a disease-relevant mouse model of COASY dysfunction.
Coenzyme A (CoA) is a vital cofactor involved in energy metabolism, lipid biosynthesis, protein modification, and epigenetic regulation. Disruptions in CoA biosynthesis have been implicated in neurometabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and COASY protein-associated neurodegeneration (CoPAN), both within the heterogeneous spectrum of Neurodegeneration with Brain Iron Accumulation (NBIA). Specifically, CoPAN results from recessive variants in the COASY gene, encoding the bifunctional CoA synthase enzyme, leading to progressive neurodegeneration, motor impairment, and metabolic abnormalities. To investigate the neuronal impact of CoA deficiency, we developed an inducible, neuron-specific Coasy deleted mouse model. Unlike previous constitutive models, this system faithfully recapitulates key clinical and molecular features of CoPAN, including motor deficits, neurodegeneration, iron dyshomeostasis, and reduced survival. Strikingly, conditional neuronal Coasy ablation triggered extensive and progressive neuroinflammation, highlighting a neglected pathogenic component and potential therapeutic target. This model thus represents a robust platform to dissect disease mechanisms and evaluate candidate treatments. Given the established neuroprotective role of peroxisome proliferator-activated receptor gamma (PPARγ), we tested leriglitazone, a novel brain-penetrant full and selective PPARγ agonist effective in other rare neurodegenerative models. Leriglitazone treatment significantly improved motor performance, restored iron homeostasis, and attenuated both neuroinflammation and neurodegeneration. This study advances our understanding of the mechanism driving CoA-related neurodegeneration, highlights neuroinflammation as a pivotal pathogenic process, and demonstrates the therapeutic potential of PPARγ activation, underscoring leriglitazone as a promising candidate for CoPAN and potentially for the broader NBIA spectrum.
2026-08-15 | From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis.
Coenzyme A (CoA) biosynthesis is a conserved, dynamically regulated pathway essential for mitochondrial energy production, fatty acid oxidation, lipid biosynthesis and protein acylation. Biallelic variants in PANK2, PPCS, PPCDC, and COASY cause rare inborn errors of CoA biosynthesis, associated with markedly different clinical phenotypes: PANK2 and COASY defects predominantly cause neurological disorders within or adjacent to the neurodegeneration with brain iron accumulation (NBIA) spectrum, whereas PPCS and PPCDC deficiencies present mainly as severe early-onset dilated cardiomyopathy. However, COASY variants can also cause pontocerebellar hypoplasia and riboflavin-responsive lipid storage myopathy. This review examines these four disorders from a metabolic perspective, integrating clinical features, experimental models, biochemical data and emerging therapeutic approaches. Current evidence indicates that disease pathogenesis cannot be explained only by global CoA depletion. Total CoA levels may be reduced in PPCS and PPCDC deficiency, but are often preserved under basal conditions in PKAN and COASY-related models. Instead, impaired compartment-specific CoA handling and failure to sustain CoA-dependent flux under increased metabolic demand are emerging as central pathogenic concepts. Perturbation of fatty acid handling, acyl-CoA/acylcarnitine balance, mitochondrial function, iron homeostasis, protein acylation and 4'-phosphopantetheinylation may contribute to tissue-selective vulnerability. Therapeutic strategies are therefore likely to require disease-specific approaches, including precursor bypass or PANK activation where pathway flux can be restored, early pantethine supplementation in cardiomyopathic forms, and downstream or gene-directed strategies for COASY-related disorders. Understanding CoA as a regulator of metabolic adaptability provides a unifying framework for interpreting both shared mechanisms and disease divergence.
2026-07-28 | Pantethine and Neurodegeneration: A Coenzyme ACentered Framework Linking Metabolism, Neuroinflammation, and Mitochondrial Dysfunction
Neurodegenerative diseases are a growing global health burden associated with aging and characterized by progressive neuronal dysfunction, metabolic failure, mitochondrial impairment, oxidative stress, and chronic neuroinflammation. Among the metabolic pathways implicated in these disorders, coenzyme A (CoA)-linked biology has emerged as a potentially important but still underexplored contributor to neuronal resilience and vulnerability. Pantethine, a disulfide derivative of pantetheine and a CoA-related metabolic precursor, has attracted attention because of its reported effects on cellular metabolism, redox balance, and inflammatory signaling. However, its relevance across neurodegenerative diseases remains unevenly defined, with direct support strongest in pantothenate kinase-associated neurodegeneration (PKAN) and more limited evidence in common disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). This narrative review critically examines the mechanistic and translational evidence linking pantethine to neurodegeneration. PKAN represents the most logical disease context for pantethine investigation because impaired CoA biosynthesis is proximal to disease pathogenesis, although pantethine remains investigational and its clinical efficacy has not been established. By contrast, proposed applications in AD and PD remain highly theoretical and hypothesis-generating. Nevertheless, research on pantethine and related CoA-restoring strategies may identify new intervention targets across neurodegenerative diseases and other disorders characterized by impaired cellular bioenergetics, including selected neuropsychiatric disorders. These possibilities require biomarker-informed, disease-specific studies that establish active-species exposure, target engagement, and clinically meaningful effects.
2026-07-10 | Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges
Neurodegeneration with brain iron accumulation (NBIA) comprises a group of rare genetic movement disorders characterized by progressive neurological deterioration, dystonia, parkinsonism, spasticity, and abnormal iron deposition in the basal ganglia. Although iron accumulation is the shared neuroradiological hallmark, most NBIA genes do not directly regulate iron metabolism. Instead, major NBIA forms arise from disruption of distinct but converging cellular pathways, including coenzyme A (CoA) biosynthesis, lipid metabolism, mitochondrial function, and autophagy. This narrative review aims to examine the pathogenic mechanisms of major NBIA disorders, namely pantothenate kinase-associated neurodegeneration (PKAN), COASY protein-associated neurodegeneration (CoPAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and beta-propeller protein-associated neurodegeneration (BPAN), and how these insights are guiding therapeutic development. Preclinical strategies aimed at restoring CoA metabolism, improving mitochondrial function, limiting lipid peroxidation, modulating autophagy, or correcting the underlying genetic defect have shown encouraging results, although none have yet reached robust clinical validation. Clinical translation remains limited by disease rarity, clinical heterogeneity, absence of validated biomarkers, and preclinical models that only partially recapitulate human pathology. Advancing the field will depend on earlier molecular diagnosis, biomarkers capable of tracking disease stage, and trial designs suited to ultra-rare populations. NBIA thus offers a paradigm for how mechanistic classification of a genetically defined disease group can redirect therapeutic strategy away from a shared radiological feature and toward pathway-specific intervention.
2026-04-30 | Neurodegeneration with Brain Iron Accumulation PANK2 and PLA2G6 Related Disorders
Abstract: Background Neurodegeneration with Brain Iron Accumulation (NBIA) disorders are rare inherited conditions characterized by progressive motor and cognitive decline due to iron deposition in the basal ganglia and cerebellum. Among the eleven genetic subtypes, Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Phospholipase A₂-Associated Neurodegeneration (PLAN) are the best-characterized models linking disrupted iron metabolism to neurodegeneration. This review synthesizes current knowledge on the molecular basis, clinical features, diagnostic challenges, and emerging therapies for PKAN and PLAN. Conclusion PKAN and PLAN result from mutations in PANK2 and PLA2G6, respectively, disrupting coenzyme A synthesis and membrane lipid remodeling. These defects lead to mitochondrial dysfunction, oxidative stress, lipid peroxidation, and ultimately ferroptosis (an iron-dependent cell death pathway). Neuroimaging, particularly the “eye-of-the-tiger” sign in PKAN and cerebellar atrophy with optic atrophy in PLAN, aids diagnosis, though genetic testing remains definitive. Current management is symptomatic, but emerging therapies, including gene therapy, iron chelation, deuterated lipids (RT001), and enzyme activators hold promise for disease modification. A practical diagnostic algorithm is proposed to facilitate early recognition. Integrative longitudinal research is essential to clarify disease progression and optimize treatment timing.
2026-04-16 | PPARγ activation by leriglitazone counteracts neurodegeneration and neuroinflammation in a disease-relevant mouse model of COASY dysfunction.
Coenzyme A (CoA) is a vital cofactor involved in energy metabolism, lipid biosynthesis, protein modification, and epigenetic regulation. Disruptions in CoA biosynthesis have been implicated in neurometabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and COASY protein-associated neurodegeneration (CoPAN), both within the heterogeneous spectrum of Neurodegeneration with Brain Iron Accumulation (NBIA). Specifically, CoPAN results from recessive variants in the COASY gene, encoding the bifunctional CoA synthase enzyme, leading to progressive neurodegeneration, motor impairment, and metabolic abnormalities. To investigate the neuronal impact of CoA deficiency, we developed an inducible, neuron-specific Coasy deleted mouse model. Unlike previous constitutive models, this system faithfully recapitulates key clinical and molecular features of CoPAN, including motor deficits, neurodegeneration, iron dyshomeostasis, and reduced survival. Strikingly, conditional neuronal Coasy ablation triggered extensive and progressive neuroinflammation, highlighting a neglected pathogenic component and potential therapeutic target. This model thus represents a robust platform to dissect disease mechanisms and evaluate candidate treatments. Given the established neuroprotective role of peroxisome proliferator-activated receptor gamma (PPARγ), we tested leriglitazone, a novel brain-penetrant full and selective PPARγ agonist effective in other rare neurodegenerative models. Leriglitazone treatment significantly improved motor performance, restored iron homeostasis, and attenuated both neuroinflammation and neurodegeneration. This study advances our understanding of the mechanism driving CoA-related neurodegeneration, highlights neuroinflammation as a pivotal pathogenic process, and demonstrates the therapeutic potential of PPARγ activation, underscoring leriglitazone as a promising candidate for CoPAN and potentially for the broader NBIA spectrum.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
6 orphan drug designations for Pantothenate kinase-associated neurodegeneration.
6 orphan drug designations for Pantothenate kinase-associated neurodegeneration.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
replication-deficient adeno-associated virus serotype 9 (AAV9) gene transfer vector carrying the pantothenate kinase 2 (PANK2) cDNA | gene therapies | FDA | 2026-07-31 | — | Susan J. Hayflick, MD PhD |
Claziprotamide | small molecules | EMA | 2021-07-19 | — | BridgeBio Europe B.V. |
Small molecule activator of pantothenate kinases | small molecules | FDA | 2020-10-07 | — | CoA Therapeutics |
S-acetyl-(S)-4'-phosphopantetheine, calcium salt | small molecules | EMA | 2016-04-28 | — | Comet Therapeutics B.V. |
Fosmetpantotenate | small molecules | EMA | 2016-02-17 | — | [INACTIVE] Travere Therapeutics Ireland Limited |
pantothenate phosphate | small molecules | FDA | 2015-05-04 | — | Retrophin, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.